JAZZ's operating cash flow of $506.1M in 2026Q3 and free cash flow margins of 32.9% to 39.4% over the last three quarters suggest the business retains substantial cash generation even as reported net income turned negative at -$483.4M.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth moderated to 10.4% in 2026Q3 from 22.3% in 2025Q3, but gross margins near 91% are repeatedly undermined by SG&A of $407.9M and large below-gross-profit charges that swing operating margin from 75.9% to -33.3%.
Jazz Pharmaceuticals secured exclusive worldwide rights to develop and commercialize SAN2355, a potential treatment for epilepsy, through a global license agreement with Saniona.
Fifteen analysts hold buy or outperform ratings on Jazz Pharmaceuticals stock, with a mean target price implying 15% upside and high conviction in the bull case.
The bull case for Jazz Pharmaceuticals is anchored to a successful launch of zanidatamab for gastroesophageal adenocarcinoma (GEA), with a Street high target of $275.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | -$3.88+3.7% vs -$4.03 | $1.2B+2.9% vs $1.2B |
Q3 2026 Aug 3, 2026 | $5.71-7.6% vs $6.18 | $1.2B+8.4% vs $1.1B |
Q2 2026 May 5, 2026 | $6.34+36.6% vs $4.64 | $1.1B+9.2% vs $979M |
Q1 2026 Feb 24, 2026 | $6.64+1.8% vs $6.52 | $1.2B+2.8% vs $1.2B |
Boston Trust Walden Corp decreased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 424,569 shares of the specialty pharmaceutical company's stock after selling 18,554 shares during the quarter.
DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies London Global Healthcare Conference on Tuesday, November 17, 2026, at 8:00 a.m. ET Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, at 8:00 a.m.
Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
Benchmark JAZZ against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Jazz Pharmaceuticals plc (JAZZ)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $234.76 | $14.75B | 73.75 | 4.88% | 4.37% | 4.62% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $36.43 | $1.43B | 39.43 | 3.63% | 5.08% | 5.53% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $45.90 | $7.7B | -9999.00 | -5.25% | -0.02% | -0.02% | — |
Jazz Pharmaceuticals plc (JAZZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Jazz Pharmaceuticals plc (JAZZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Oct 26, 2026·SEC
Oct 9, 2026·SEC
Get notified when JAZZ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Jazz Pharmaceuticals plc (JAZZ) stock FAQ — growth, dividends, profitability & financials explained
Jazz Pharmaceuticals plc (JAZZ) reported $4.72B in revenue over the trailing twelve months. Revenue was $4.27B in fiscal year 2025. That is 19803% more than the $21.4M of fiscal year 2005.
Jazz Pharmaceuticals plc (JAZZ) grew revenue by 13.5% over the trailing twelve months, compared with the twelve months before.
Yes. Jazz Pharmaceuticals plc (JAZZ) earned $206.0M in net income over the trailing twelve months (a 4.4% net margin).
Jazz Pharmaceuticals plc (JAZZ) had a return on equity (ROE) of 4.6% over the trailing twelve months. That is below the market's typical 10-15%.
Jazz Pharmaceuticals plc (JAZZ) generated $1.57B in free cash flow over the trailing twelve months.
